N/A
N=854
Lumigan® in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)
Glaucoma, Open-Angle · Ocular Hypertension
Bottom Line
View on ClinicalTrials.gov: NCT01628588 ↗Enrolled (actual)
854
Serious AEs
0.0%
Results posted
Sep 2012
Primary outcome: Primary: Change From Baseline in Intraocular Pressure (IOP) — 19.0; -4.0; 20.0; -5.0 Millimeters of Mercury (mmHg)
Study Design & Population
- Study type
- Observational
- Phase
- N/A
- Interventions
- bimatoprost 0.01% (Drug)
- Age
- Pediatric, Adult, Older Adult
- Sex
- All
- Sponsor
- Allergan
- Primary completion
- Dec 2010
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Change From Baseline in Intraocular Pressure (IOP) |
19.0; -4.0; 20.0; -5.0 | — |
| SECONDARY Patient Assessment of Tolerability Using a 4-Point Scale |
755 | — |
| SECONDARY Physician Assessment of Tolerability Using a 4-Point Scale |
788 | — |
| SECONDARY Patients Who Discontinued Use of Lumigan® Prior to 14 Weeks |
70 | — |
| SECONDARY Patients Who Will Continue Use of Lumigan® After 14 Weeks |
723 | — |
Summary
This is an observational study of Lumigan® 0.01% (bimatoprost) treatment in clinical practice for patients with Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT).
Eligibility Criteria
Inclusion Criteria
- Diagnosis of primary open angle glaucoma or ocular hypertension
- Prescribed Lumigan®
Exclusion Criteria
- None
Data sourced from ClinicalTrials.gov (NCT01628588). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.